Histogen Inc. (NASDAQ:HSTO – Get Free Report) fell 33.3% during trading on Wednesday . The stock traded as low as $0.20 and last traded at $0.20. 478 shares were traded during mid-day trading, a decline of 97% from the average session volume of 15,401 shares. The stock had previously closed at $0.30.
Histogen Trading Down 33.3 %
The stock has a market cap of $854,000.00, a P/E ratio of -0.07 and a beta of 1.16. The firm’s 50-day simple moving average is $0.24 and its 200 day simple moving average is $0.32.
Histogen Company Profile
Histogen Inc, a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases.
See Also
- Five stocks we like better than Histogen
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- AbbVie Stock: A Perfect Dip for Investors to Buy
- 3 Tickers Leading a Meme Stock Revival
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Histogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogen and related companies with MarketBeat.com's FREE daily email newsletter.
